Table 2 Elevated (↑) or decreased (↓) risk of restenosis, target laesion vascularization (TLR), death or myocardial infarction (MI) of the different groups of glucose lowering agents after PCI.
Risk Modulation of Glucose Lowering Agents in Diabetics After PCI | ||||
|---|---|---|---|---|
Agent | Restenosis | TLR | Death | MI |
TZDs | ↓ | ↓ | ↓ | - |
Sulfonylurea | ↑ | - | ↑ | - |
Biguanides | - | ↓ | - | ↓ |
Insulin | ↑ | ↑ | ↑ | ↑ |